Nav: Home

Maintaining shelf-stable drugs

July 22, 2019

A new mathematical model describes how highly concentrated antibody solutions separate into different phases, similar to an oil and water mixture. This separation can reduce the stability and shelf-life of some drugs that use monoclonal antibodies, including some used to treat autoimmune diseases and cancer. A team of scientists from Penn State and MedImmune, LLC (now AstraZeneca) investigated the thermodynamics and kinetics, the relationships between temperature, energy, and the rates of chemical reactions, of the phenomenon using an innovative method that allows for the rapid study of multiple samples at once. A paper describing their model appears July 22, 2019, in the journal Proceedings of the National Academy of Sciences.

Many drugs today are stored as solids and dissolved in IV bags for delivery to patients, but the pharmaceutical industry has been moving toward drugs that can be stored as liquids and given via a shot. Some of these drug solutions, like those used to treat autoimmune diseases and some cancers, contain high concentrations of monoclonal antibodies--proteins that attach to foreign substances in the body, like bacteria and viruses, flagging them for destruction by the patient's immune system.

"Highly concentrated protein solutions can separate into different phases, like a vinaigrette salad dressing separating into layers over time," said Bradley Rogers, graduate student in chemistry at Penn State and first author of the paper. "Phase separation is one of the pathways that makes these drugs unstable and unsuitable for use. The classical method to understand this process involves manipulating the temperature of one sample over time. We used a temperature gradient microfluidics platform to quickly look at many temperatures simultaneously."

An antibody-rich solution begins as a clear liquid at room temperature, but as the solution cools, cloudy droplets begin to form. Over time, the droplets settle to the bottom, with dilute liquid remaining on top, making the sample appear clear. The team used an innovative device that creates a range of temperatures across a temperature gradient and used a technique called dark-field imaging to measure how quickly this process occurs. Then the team calculated a variety of parameters to better understand the thermodynamics and kinetics of the system, including the temperatures at which phase transitions occur and the amount of energy it takes to go from one phase to the next--activation energies.

"We observed that the rate that a solution separates into two phases has a strange dependence on temperature," said Rogers. "This relationship is much more complicated for concentrated antibody solutions than it is for other systems. We spent a long time trying to make sense of the data, but we eventually developed a model that explains what we are seeing."

The model describes how antibody molecules stick together as the temperature decreases, forming droplets that grow as additional molecules join. This reversible process happens more and more quickly with decreasing temperature, because the solution gets increasingly saturated with free antibody molecules. Then, as the solution continues to cool, droplets stick to other droplets and settle to the bottom. At even colder temperatures, the solution forms a gel and cannot complete the separation, even over the course of a month.

"In a single experiment, we can visualize the homogenous clear solution, the cloudy solution as droplets begin to form, the phase-separated liquid, and the gel," said Paul Cremer, J. Lloyd Huck Chair in Natural Sciences at Penn State and senior author of the paper. "Previous research described these different states, and our model describes the mathematics and temperature-dependent kinetics behind what we believe is happening."

Next, the research team plans to investigate if their model can explain phase separation in other systems. They also plan to test whether parameters gathered from this type of experiment can predict stability and shelf-life of therapeutics.

"If these parameters can help us predict stability and shelf life, we may be able to select better drug candidates," said Rogers. "We may also be able to determine the ideal solution properties for a promising drug candidate to keep it stable."

In addition to Rogers and Cremer, the research team includes Kelvin Rembert, Matthew Poyton, Halil Okur, Amanda Kale, and Tinglu Yang at Penn State and Jifeng Zhang from AstraZeneca. The work was supported by MedImmune LLC (now AstraZeneca). Additional support was provided by the National Science Foundation.
-end-


Penn State

Related Antibody Articles:

It's Fab! A hidden touch of antibody
Antibodies are key players in our immune system and have been used as biopharmaceuticals.
Lupus antibody target identified
Researchers have identified a specific target of antibodies that are implicated in the neuropsychiatric symptoms of lupus, according to human research published in JNeurosci.
It's not an antibody, it's a frankenbody: A new tool for live-cell imaging
Researchers from Colorado State University and the Tokyo Institute of Technology have added a new tool to the arsenal of antibody-based probes, but with a powerful distinction: Their genetically encoded probe works in living cells.
Metabolomic profiling of antibody response to periodontal pathogens
At the 97th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 48th Annual Meeting of the American Association for Dental Research (AADR) and the 43rd Annual Meeting of the Canadian Association for Dental Research (CADR), Jaakko Leskela, University of Helsinki, Finland, gave an oral presentation on 'Metabolomic Profiling of Antibody Response to Periodontal Pathogens.'
An unexpected mode of action for an antibody
Studies of human monoclonal antibodies isolated from survivors of coronavirus-induced severe acute respiratory syndrome (SARS) or Middle-East respiratory syndrome (MERS) are unveiling surprising immune defense tactics against fatal viruses.
New antibody analysis accelerates rational vaccine design
''We can now watch antibody responses evolve almost in real time,'' says Lars Hangartner, Ph.D., a Scripps Research associate professor.
Newly described human antibody prevents malaria in mice
Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum.
Three-in-one antibody protects monkeys from HIV-like virus
A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers report in Science today.
Novel small antibody fragment: A valuable tool in crystallography
Achieving quality diffracting crystals remains the major bottleneck in macromolecular X-ray crystallography.
New therapeutic antibody for dog cancers
Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers.
More Antibody News and Antibody Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.